Chinese
Home
About Livzon
Chairman's Speech
Milestones
Leaders' Caring
Company Honors
Cultural Vision
Contact Us
Media
Livzon News
Employment system
Investor Relations
Company Governance
Announcement
Financial Reports
ESG Report
Shareholder Returns
Stock Information
Sustainable Development
Human Development
Board Diversity Policy
Business Ethics
Supplier
Environment, Occupational Health and Safety (EHS)
Philanthropy
Privacy Policy
Tax policy
ESG Ratings and Honors
Product
Leading Products
Products List
ADR Reporting
R&D
R&D Platforms
Livzon microspheres
Livzon Bio
Livzon Research Institute
R&D Achievements
IP Achievements
Overseas Market
Overseas Business
Specialty Products
Certificates
Contact us
Join Us
Social Recruitment
Campus Recruitment
Compensation and Benefits
Appeal Against
Bidding procurement
Tender Announcement
Supplier Login
Supervision and Reporting
Contact information
Online message
Labor System
New Lijuzhu Magazine
Lizhu Pharmaceutical and Tongyuan Kang Pharmaceutical have reached a multi-target kinase inhibitor equity transaction in the Greater China region.
2020-09-02
In 2019, the list of the top 100 pharmaceutical companies in China was released, and Chairman Zhu Baoguo participated in the roundtable forum.
LIZHU Group released the 2019 Environmental, Social and Governance Report
Since the national launch of a new round of healthcare system reform in 2019, our country has gradually established a comprehensive basic medical security system over the past decade, with various key health indicators for residents generally better than the average level of middle and high-income countries. In 2019, the revised "Prohibition of Certain Goods Management Law of the People's Republic of China" was passed, and the State Council's medical reform deepening group released "Several Policy Measures for Further Deepening the Reform of the Medical and Health System," marking that the new medical reform is entering the "fast lane" and is "restarting" towards the goal of universal health coverage.
2020-04-15
LIZHU Group 2019 Annual Report
2020-04-14
Lizhu Pharmaceutical's wholly-owned subsidiary leads the Series B financing of Jiangsu New Element.
2020-03-11
Lijuzhu Group included in the Hang Seng Sustainable Development Corporate Benchmark Index
Lijun Group has been included in the Hang Seng A-Share Sustainable Development Enterprises Benchmark Index, which recognizes Lijun Group's commitment to sustainable development and reflects its outstanding performance in the areas of business development, environment, society, and corporate governance. Lijun will continue to innovate and strive for progress, bringing the best returns to society and investors through excellent business performance, contributing to a healthy China.
2019-08-20
A picture to understand the 2019 half-year report of Livzon Pharmaceutical Group
In the first half of 2019, Livzon's operating income was 4.939 billion yuan, a year-on-year increase of 8.20%; net profit was 835 million yuan, a year-on-year increase of 23.50%; net profit attributable to the parent company was 739 million yuan, a year-on-year increase of 16.67%; net profit attributable to the parent company after deducting non-recurring gains and losses was 659 million yuan, a year-on-year increase of 15.32%.
2019-08-17
Hou Xuemei: Focused on innovative drug research for thirty-two years, benefiting millions of patients.
From the special topic: Guangdong News Broadcast Guangdong Satellite TV News Broadcast "Patriotic Feelings and Strivers" series report: Hou Xuemei is the chief scientist of Livzon Pharmaceutical Group Research Institute. She has focused on research and development for 32 years in her scientific research position, leading the team to develop a new drug for the digestive field, Esomeprazole, which has become a milestone in the history of new drug development in China. Let's turn the clock back to 2001. At that time, 70% of domestic gastrointestinal medications were proton pump inhibitors, and the four drugs on the market were all monopolized by foreign large enterprises, making the Price very expensive. Hou Xuemei made up her mind that to break the monopoly, she had to carve out a bloody path and create her own innovative drug. Livzon Pharmaceutical Group Research Institute Chief Scientist.
2019-04-12
